Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Durvalumab Following SBRT in Stage I NSCLC
NCT03446547Phase 2Completed
- Sponsor
- Region Västra Götaland
- Start
- Dec 2017
- Primary completion
- Oct 2025
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 3
01
Overview
A Phase 2 trial of durvalumab in non-small cell lung cancer (NSCLC), sponsored by Region Västra Götaland. Started Dec 2017; status: completed.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03446547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03446547.